In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…
read moreHow close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…
read moreThe US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…
read moreOn May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…
read moreThe US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…
read moreThis year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…
read moreMigraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications for other conditions. They are…
read moreI had the chance to meet up with Professor Sprenger at ECTRIMS-ACTRIMS in Paris last week. We discussed the TEMSO study, which has been evaluating the long-term treatment effect of teriflunomide…
read moreData presented at the recent 7th joint ECTRIMS-ACTRIMS meeting in Paris delved deeper into the efficacy of siponimod in the treatment of secondary progressive MS (SPMS). As Robert Fox (Mellen…
read moreThe development and characterisation of biomarkers in multiple sclerosis (MS) could be a crucial step in understanding disease pathways, as well as the therapeutic mechanisms of disease-modifying treatments. So was…
read more- 1
- 2